Takeoka Keiko, Watanabe Mikio, Matsuzuka Fumio, Miyauchi Akira, Iwatani Yoshinori
Division of Biomedical Informatics, Course of Health Science, Osaka University Graduate School of Medicine, Suita, Osaka, Japan.
Thyroid. 2004 Mar;14(3):201-5. doi: 10.1089/105072504773297876.
The intractability of Graves' disease (GD) and the severity of Hashimoto's disease (HD) vary among patients. We previously reported that peripheral immunoglobulin (Ig) G3-secreting cells were increased in patients with intractable GD (i.e., requiring continuous antithyroid drug therapy). Isotype switching to IgG3 is induced by interleukin (IL)-4 and IL-10. To clarify which of these cytokines is related to the intractability or severity of autoimmune thyroid disease (AITD), we examined the serum concentrations of IL-10 and IL-4 by enzyme immunoassay in 166 patients with AITD and in 53 healthy controls. The serum IL-10 concentration was significantly higher in patients with GD and continuously positive for thyrotropin (TSH) receptor antibody (TRAb) despite more than 5 years of antithyroid drugs treatment than in patients with GD in remission. The serum IL-4 concentration did not differ between these two groups of patients. However, the serum IL-10 concentration was not related to the severity of HD. These results indicate that IL-10, but not IL-4, is related to the intractability of GD, but not to the severity of HD.
格雷夫斯病（GD）的难治性和桥本甲状腺炎（HD）的严重程度在患者之间存在差异。我们之前报道过，难治性GD患者（即需要持续抗甲状腺药物治疗的患者）外周分泌免疫球蛋白（Ig）G3的细胞增多。向IgG3的同种型转换是由白细胞介素（IL）-4和IL-10诱导的。为了阐明这些细胞因子中的哪一种与自身免疫性甲状腺疾病（AITD）的难治性或严重程度相关，我们通过酶免疫测定法检测了166例AITD患者和53例健康对照者血清中IL-10和IL-4的浓度。在接受抗甲状腺药物治疗超过5年但促甲状腺激素（TSH）受体抗体（TRAb）仍持续呈阳性的GD患者中，血清IL-10浓度显著高于处于缓解期的GD患者。这两组患者的血清IL-4浓度没有差异。然而，血清IL-10浓度与HD的严重程度无关。这些结果表明，与GD的难治性相关的是IL-10而非IL-4，且IL-10与HD的严重程度无关。
